50 mg or 100 mg vildagliptin, or twice-daily doses of placebo or 25 mg vildagliptin. Efficacy was determined by reduction in glycosylated hemoglobin levels, a measure of long-term glycemia.

However, a recent study [46] showed that vildagliptin largely (by 85%) inhibited the triglyceride response to ingestion of a fat-rich meal following a 4-week treatment at 50 mg twice daily in ...